MyFinsight
Home
Blog
About
Net decrease in cash
and restricted cash
-$9,404K
(69.60%↑ Y/Y)
Legal settlement
liability
$4,000K
Change in deferred r&d
services and r&d funding...
$2,904K
Accrued expenses and
other current...
$2,297K
(660.24%↑ Y/Y)
Stock-based compensation
$1,213K
(-36.62%↓ Y/Y)
Deferred revenue
$304K
(-36.80%↓ Y/Y)
Non-cash r&d expense
related to torii warrant...
$192K
Amortization of finance lease
right-of-use asset
$113K
(-31.52%↓ Y/Y)
Amortization of operating
lease right-of-use...
$79K
(-45.89%↓ Y/Y)
Depreciation expense
$15K
(-84.38%↓ Y/Y)
Net cash used in
operating activities
-$9,278K
(59.17%↑ Y/Y)
Net cash used in
financing activities
-$126K
(98.47%↑ Y/Y)
Canceled cashflow
$11,117K
Net loss
-$13,153K
(-37.90%↓ Y/Y)
Repayment of finance lease
$126K
(-31.15%↓ Y/Y)
Accounts receivable
$3,215K
(-64.84%↓ Y/Y)
Insurance recovery asset
$2,302K
Inventory
$738K
(1150.85%↑ Y/Y)
Accounts payable
-$590K
(-238.82%↓ Y/Y)
Prepaid expenses and
other assets
$251K
(130.68%↑ Y/Y)
Operating lease liability
-$84K
(45.45%↑ Y/Y)
Collaboration receivable,
billed and unbilled
$62K
(-99.24%↓ Y/Y)
Back
Back
Cash Flow
Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. (VRCA)
source: myfinsight.com